Chandrakant Panchal
Director/Board Member chez CANADIAN OIL RECOVERY & REMEDIATION ENTERPRISES LTD.
Fortune : 118 558 $ au 31/03/2024
Profil
Chandrakant J.
Panchal was the founder of Procyon Biopharma, Inc. (founded in 1989) where he held the title of Chief Scientific Officer & Senior Executive VP from 1999 to 2006.
He is also the founder of Axcelon Biopolymers Corp.
(founded in 2001) where he serves as the Chief Executive Officer.
Currently, Dr. Panchal holds multiple positions.
He is a Director at CardioGenics, Inc. He is also an Independent Director at Canadian Oil Recovery & Remediation Enterprises Ltd.
since 2008.
Additionally, he is the Managing Director at Panford Investment Corp.
since 2008.
Furthermore, he serves as the President of Mentra Nova Enterprises, Inc.Dr. Panchal has held several former positions.
He was the Chairman of Panacea Global, Inc. He also served as the Chairman of Pure Global Cannabis, Inc. from 2018 to 2020.
He has been a Director at JAG Media Holdings, Inc., Pacific Software, Inc., Rodocanachi Capital, Inc., and A.C.
Simmonds & Sons, Inc. He was a Director at Avivagen, Inc. and Toronto Innovation Acceleration Partners from 2009 to 2015.
He served as a Director at CardioGenics Holdings, Inc. from 1986 to 2010.
He is currently a Director at Medicenna Therapeutics, Inc. since 2017 and Medicenna Therapeutics Corp.
since 2016, where he holds the position of Lead Independent Non-Executive Director.
He is also an Independent Director at Avicanna, Inc. since 2016.
Additionally, he is an Independent Director at Atlantic Coastal Acquisition Corp.
from 2023 to 2024.
He was the Executive VP-Business Development & Licensing at Ambrilia Biopharma, Inc. from 2006 to 2008.
Dr. Panchal's education includes an undergraduate degree from the University of Toronto in 1972, a graduate degree from the University of Toronto in 1975, and a doctorate degree from the University of Western Ontario in 1979.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AVICANNA INC
0,33% | 14/04/2023 | 291 959 ( 0,33% ) | 114 448 $ | 31/03/2024 |
| 10/06/2023 | 3 000 ( 0,00% ) | 4 110 $ | 31/03/2024 |
Postes actifs de Chandrakant Panchal
| Sociétés | Poste | Début |
|---|---|---|
| CANADIAN OIL RECOVERY & REMEDIATION ENTERPRISES LTD. | Director/Board Member | 25/11/2008 |
| Panford Investment Corp. | Corporate Officer/Principal | 01/10/2008 |
| Mentra Nova Enterprises, Inc. | President | - |
CardioGenics, Inc.
 CardioGenics, Inc. BiotechnologyHealth Technology CardioGenics, Inc. manufactures biotechnology and medical devices. It develops in-vitro-diagnostics cardiac testing products. The company was founded in 1997 and is headquartered in Mississauga, Canada. | Director/Board Member | 12/11/2009 |
Axcelon Biopolymers Corp.
 Axcelon Biopolymers Corp. Electronic Equipment/InstrumentsElectronic Technology Axcelon Biopolymers Corp. provides medical devices for human health applications. It provides devices to those companies which uses nanotechnology to biodegradable polymer design and applications. Its technology includes stent coating, ophthalmology, drug delivery and regenerative medicine. The company is headquartered in Toronto, Canada | Chief Executive Officer | 01/01/2008 |
Anciens postes connus de Chandrakant Panchal
| Sociétés | Poste | Fin |
|---|---|---|
| ATLANTIC COASTAL ACQUISITION CORP. | Director/Board Member | 14/02/2024 |
| MEDICENNA THERAPEUTICS CORP. | Director/Board Member | 28/09/2023 |
| AVICANNA INC. | Chairman | 01/09/2023 |
Medicenna Therapeutics, Inc.
 Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Director/Board Member | 01/09/2023 |
| ░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░ | - |
Formation de Chandrakant Panchal
| University of Toronto | Graduate Degree |
| University of Western Ontario | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| PACIFIC SOFTWARE, INC. | Technology Services |
| AVIVAGEN INC. | Health Technology |
| CANADIAN OIL RECOVERY & REMEDIATION ENTERPRISES LTD. | Industrial Services |
| CARDIOGENICS HOLDINGS INC | Health Technology |
| MEDICENNA THERAPEUTICS CORP. | Health Technology |
| AVICANNA INC. | Health Technology |
| PURE GLOBAL CANNABIS INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
JAG Media Holdings, Inc.
 JAG Media Holdings, Inc. Internet Software/ServicesTechnology Services JAG Media Holdings provides subscribers with investment news (called JagNotes) via its Web site and, to a lesser extent, fax. The site also offers some free information. The company has launched a division called The Company Voice, which offers public and investor relations services to public companies | Technology Services |
Procyon Biopharma, Inc.
 Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | Commercial Services |
Rodocanachi Capital, Inc.
 Rodocanachi Capital, Inc. Financial ConglomeratesFinance Rodocanachi Capital, Inc. operates as a capital pool company. The company was founded in March 5, 2008 and is headquartered in Montreal, Canada. | Finance |
A.C. Simmonds & Sons, Inc.
 A.C. Simmonds & Sons, Inc. Movies/EntertainmentConsumer Services A.C. Simmonds & Sons, Inc. engages in identifying opportunities prime for consolidation, expansion and further development. It is focused on acquiring businesses for expansion and development food, manufacturing, transportation, mold remediation, oil and gas, and leisure and recreation industries. The company was founded in 1918 and is headquartered in King City, Canada. | Consumer Services |
CardioGenics, Inc.
CardioGenics, Inc. BiotechnologyHealth Technology CardioGenics, Inc. manufactures biotechnology and medical devices. It develops in-vitro-diagnostics cardiac testing products. The company was founded in 1997 and is headquartered in Mississauga, Canada. | Health Technology |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Toronto Innovation Acceleration Partners
 Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | Health Technology |
Axcelon Biopolymers Corp.
Axcelon Biopolymers Corp. Electronic Equipment/InstrumentsElectronic Technology Axcelon Biopolymers Corp. provides medical devices for human health applications. It provides devices to those companies which uses nanotechnology to biodegradable polymer design and applications. Its technology includes stent coating, ophthalmology, drug delivery and regenerative medicine. The company is headquartered in Toronto, Canada | Electronic Technology |
| Mentra Nova Enterprises, Inc. | |
| Panford Investment Corp. | |
Medicenna Therapeutics, Inc.
Medicenna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA. | Health Technology |
Atlantic Coastal Acquisition Corp.
 Atlantic Coastal Acquisition Corp. Financial ConglomeratesFinance Atlantic Coastal Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 7, 2020 and is headquartered in New York, NY. | Finance |
Panacea Global, Inc.
 Panacea Global, Inc. Medical SpecialtiesHealth Technology Panacea Global, Inc. is a biotechnology company focused on the discovering, developing and commercializing of diagnostic products for the management of cancer. The company provides blood, serum and tissue tests to diagnose and monitor cancer through a licensing agreement with Panacea Pharmaceuticals. Its current product line allows for accurate detection of the most common forms of cancer, which includes diagnostic tests for lung, breast, prostate and colon cancers. The company was founded in 1995 and is headquartered in Richmond Hill, Canada. | Health Technology |
